| Bioactivity | Ethyl linoleate-13C18 is the 13C labeled Ethyl linoleate. Ethyl linoleate inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators[1]. |
| Invitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
| Name | Ethyl linoleate-13C18 |
| CAS | 202114-63-4 |
| Formula | C213C18H36O2 |
| Molar Mass | 326.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |
Ethyl linoleate-13C18
CAS: 202114-63-4 F: C213C18H36O2 W: 326.37
Ethyl linoleate-13C18 is the 13C labeled Ethyl linoleate. Ethyl linoleate inhibit the development of atherosclerotic les
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.